PATENT CLAIM ANALYSIS

Application Number: 16206694
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "450000"]

Abstract:
Novel encapsulated umirolimus and umirolimus polymer conjugate formulations having enhanced permeability and retention at tumor sites. Also provided are methods for treating cancer by administering the umirolimus formulations.

Claim (Index 14):
The method of  claim 13 , wherein the cancer is selected from the group consisting of gastric cancer, pancreatic cancer, myeloma, lung cancer, ovarian cancer, liver cancer, chronic myelogenous leukemia, colorectal cancer, and breast cancer.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14093876', '14765620', '13916129', '12761588', '12731781']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7553539901299495
- 35 USC 102 Novelty (BERT): 0.5064073762512759
- Combined Prediction Score: 0.7304593287420822
- Mean Citation Score: 219.67006
- Max Citation Score: 284.49216
- Similarity Product: 215.7671526821136

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test